Evelo Biosciences Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Evelo Biosciences Inc (EVLO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
API endpoints for this dataset
Evelo Biosciences Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Evelo Biosciences Inc | - | - | - | Yes |
| Competitors combined (141) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
EVLO Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 2 | Moderna Inc | 282.9% | Outperformed |
| 3 | An2 Therapeutics Inc | 282.9% | Outperformed |
| 4 | Regulus Therapeutics Inc | 282.9% | Outperformed |
| 5 | Centessa Pharmaceuticals Plc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Evelo Biosciences Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Evelo Biosciences Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Evelo Biosciences Inc | 0.00 | - |
| Abbvie Inc | 522,793.16 | 66,014.00 |
| Amgen Inc | 254,255.82 | 38,903.00 |
| Pfizer Inc | 166,146.39 | 63,625.00 |
| Vertex Pharmaceuticals Inc | 137,450.72 | 12,951.60 |
| Bristol myers Squibb Company | 130,221.79 | 50,033.00 |
| SUBTOTAL | 1,915,690.52 | 354,155.21 |
Sign in to see all competitors of Evelo Biosciences Inc .
Sources: Evelo Biosciences Inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Evelo Biosciences Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Evelo Biosciences Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Teva Pharmaceutical Industries Limited | United States 42.55 % |
| Biogen Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Evelo Biosciences Inc .
Evelo Biosciences Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Evelo Biosciences Inc | 0 | - | -2,744,967 |
| Abbvie Inc | 522,793 | 1,158,140 | 181,509 |
| Amgen Inc | 254,256 | 2,992,538 | 722,385 |
| Pfizer Inc | 166,146 | 848,333 | 54,160 |
| Vertex Pharmaceuticals Inc | 137,451 | 31,979,259 | 9,817,037 |
| Bristol myers Squibb Company | 130,222 | 1,539,477 | 284,338 |
| PEERS TOTAL | 1,915,691 | 1,048,265 | 97,970 |
Sign in to see all peers for Evelo Biosciences Inc .
Evelo Biosciences Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Pfizer Inc | United States 63.93 % |
| Vertex Pharmaceuticals Inc | United States 63.04 % |
| Bristol myers Squibb Company | United States 69.43 % |
| Teva Pharmaceutical Industries Limited | Europe 30.49 % |
| Beone Medicines Ltd | United States 54.39 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Evelo Biosciences Inc .
Evelo Biosciences Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 490 companies in Evelo Biosciences Inc's industry classification, broader than the peer set above. Market cap in millions of $.Evelo Biosciences Inc ranks #0 of 490 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 999, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,290,056 | 24.11 % |
| 2 | Johnson and Johnson | 697,259 | 13.03 % |
| 3 | Abbvie Inc | 522,498 | 9.76 % |
| 4 | Merck and Co Inc | 364,967 | 6.82 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Evelo Biosciences Inc | 0 | 0.00 % |
Market cap and industry share for the rest of Evelo Biosciences Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-12.
Evelo Biosciences Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (447 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.2x | - |
| EV / EBITDA | - | 15.2x | - |
| P/B | -4.5x | 4.2x | -8.8x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | - | -9.68 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Evelo Biosciences Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Revenue Growth | - | - | - | - |
| Operating Margin | - | - | - | - |
| Return on Invested Capital | -43.76 % | -70.34 % | -71.65 % | -148.22 % |
| P/E | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Evelo Biosciences Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 999 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Evelo Biosciences Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Evelo Biosciences Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Evelo Biosciences Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (51.80 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-18.6% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Evelo Biosciences Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Evelo Biosciences Inc | 0.61 | 0.68 | - |
| Abbvie Inc | 0.19 | 0.79 | - |
| Amgen Inc | 0.49 | 1.31 | 5.27 |
| Pfizer Inc | 0.04 | 1.27 | 0.72 |
| Vertex Pharmaceuticals Inc | 1.30 | 2.83 | 0.06 |
| Bristol myers Squibb Company | 0.48 | 1.44 | 2.12 |
Sign in to see all peers for Evelo Biosciences Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Evelo Biosciences Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Evelo Biosciences Inc | Q3 2023 | - | - |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Amgen Inc | Q3 2026 | +8.5 % | +20.1 % |
| Pfizer Inc | Q3 2026 | -0.4 % | -8.7 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +11.8 % | -39.6 % |
| Bristol myers Squibb Company | Q3 2026 | +6.9 % | -1.5 % |
| PEERS TOTAL | +10.0 % | +65.6 % |
Sign in to see all peers for Evelo Biosciences Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Evelo Biosciences Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Evelo Biosciences Inc | Q3 2023 | - | +422.2 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Amgen Inc | Q3 2026 | -9.5 % | +34.6 % |
| Pfizer Inc | Q3 2026 | -3.5 % | -4.8 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +26.8 % | -4.4 % |
| Bristol myers Squibb Company | Q3 2026 | +20.7 % | +7.5 % |
Sign in to see all peers for Evelo Biosciences Inc .
Evelo Biosciences Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Evelo Biosciences Inc | - | - | - |
| Abbvie Inc | 7.48% | 12.87% | - |
| Amgen Inc | 10.02% | 13.64% | 85.59% |
| Pfizer Inc | 1.98% | 2.34% | 4.62% |
| Vertex Pharmaceuticals Inc | 14.16% | 16.63% | 20.08% |
| Bristol myers Squibb Company | 10.47% | 13.59% | 43.83% |
Sign in to see all peers for Evelo Biosciences Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Evelo Biosciences Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Evelo Biosciences Inc | - | - |
| Abbvie Inc | 50.78 | 7.92 |
| Amgen Inc | 27.00 | 6.54 |
| Pfizer Inc | 41.12 | 2.61 |
| Vertex Pharmaceuticals Inc | 34.73 | 10.61 |
| Bristol myers Squibb Company | 14.06 | 2.60 |
| PEERS AVERAGE | 58.02 | 5.41 |
Sign in to see all peers for Evelo Biosciences Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.